Cargando...
Clinical and molecular distinctions in patients with refractory colon cancer who benefit from regorafenib treatment
Regorafenib (Stivarga, BAY 73-4506; Bayer Pharma AG, Berlin, Germany) is a novel oral multikinase inhibitor that blocks the activity of several protein kinases. However, few guidelines exist for novel biomarkers to select patients who will likely benefit from regorafenib treatment. Metastatic colore...
Gardado en:
| Publicado en: | Ther Adv Med Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
SAGE Publications
2020
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7649869/ https://ncbi.nlm.nih.gov/pubmed/33224274 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835920965842 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|